Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia
Acute myeloid leukemia (AML), a heterogeneous hematopoietic cancer prevalent in adults,
has been a leading cause of leukemia-associated deaths for decades. Despite …
has been a leading cause of leukemia-associated deaths for decades. Despite …
[HTML][HTML] Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia
ME Leifheit, G Johnson, TM Kuzel… - International Journal of …, 2024 - mdpi.com
FMS-like tyrosine kinase 3 (FLT3) mutations are genetic changes found in approximately
thirty percent of patients with acute myeloid leukemia (AML). FLT3 mutations in AML …
thirty percent of patients with acute myeloid leukemia (AML). FLT3 mutations in AML …
Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9‐dependent AML
M Lambert, S Jambon, MA Bouhlel, S Depauw… - …, 2024 - Wiley Online Library
The mainstay of acute myeloid leukemia (AML) treatment still relies on traditional
chemotherapy, with a survival rate of approximately 30% for patients under 65 years of age …
chemotherapy, with a survival rate of approximately 30% for patients under 65 years of age …
Case report: Successful combination of CLL1 CAR-T therapy and hematopoietic stem cell transplantation in a 73-year-old patient diagnosed with refractory acute …
Y Zhao, H Wang, Y Zhang, Y Zhang, X Zhang… - Frontiers in …, 2024 - frontiersin.org
The incidence of Acute myeloid leukemia (AML) increases with advancing age, and the
prognosis for elderly patients is significantly poorer compared to younger patients. Although …
prognosis for elderly patients is significantly poorer compared to younger patients. Although …
[HTML][HTML] Flow cytometry in acute myeloid leukemia and detection of minimal residual disease
Q Cai, H Lan, D Yi, B Xian, L Zidan, J Li, Z Liao - Clinica Chimica Acta, 2024 - Elsevier
Acute myeloid leukemia (AML) is a common type of acute leukemia (AL), belonging to
malignant tumors of the hematopoietic system with the characteristics of rapid disease …
malignant tumors of the hematopoietic system with the characteristics of rapid disease …
Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome
A Alhajahjeh, JP Bewersdorf, RP Bystrom… - Leukemia & …, 2024 - Taylor & Francis
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by
diverse genetic alterations, each with distinct clinical implications. Chromosome 3 inversion …
diverse genetic alterations, each with distinct clinical implications. Chromosome 3 inversion …
Machine Learning Predicts 30-Day Outcome among Acute Myeloid Leukemia Patients: A Single-Center, Retrospective, Cohort Study
Acute myeloid leukemia (AML) is a clinical emergency requiring treatment and results in
high 30-day (D30) mortality. In this study, the prediction of D30 survival was studied using a …
high 30-day (D30) mortality. In this study, the prediction of D30 survival was studied using a …
[HTML][HTML] The Effects of ABT-199 and Dihydroartemisinin Combination on Cell Growth and Apoptosis in Human U937 and KG-1 Cancer Cells
R Nazmabadi, M Pooladi, J Amri… - Asian Pacific Journal …, 2024 - ncbi.nlm.nih.gov
Methods: Cell proliferation and survival were assessed by trypan blue staining and MTT
assay, respectively. Cell apoptosis was measured by Hoechst 33342 staining and caspase …
assay, respectively. Cell apoptosis was measured by Hoechst 33342 staining and caspase …
[HTML][HTML] Formononetin and dihydroartemisinin act synergistically to induce apoptosis in human acute myeloid leukemia cell lines
Y Abbasi, M Pooladi, R Nazmabadi, J Amri… - Cell Journal …, 2024 - ncbi.nlm.nih.gov
Objective: Enhanced cell survival and drug resistance in tumor cells have been linked to the
overexpression of antiapoptotic members of the Bcl-2 family proteins, including Bcl-2 and …
overexpression of antiapoptotic members of the Bcl-2 family proteins, including Bcl-2 and …
BCL2L13 protein prevents apoptosis in acute myeloid leukemia cells
JH Kim, HS Kim, S Lee - Oncologie, 2023 - degruyter.com
Objectives The B cell lymphoma-2 (BCL-2) protein group is essential for regulating
apoptosis. BCL2L13 harbors all BH domains present in the BCL-2 protein family in addition …
apoptosis. BCL2L13 harbors all BH domains present in the BCL-2 protein family in addition …